Evidence-Based Medicine Guidelines
SGLT-2 inhibitors in type 2 diabetes
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"SGLT-2 Inhibitors in Type 2 Diabetes." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/1305247/all/SGLT_2_inhibitors_in_type_2_diabetes.
SGLT-2 inhibitors in type 2 diabetes. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305247/all/SGLT_2_inhibitors_in_type_2_diabetes. Accessed October 11, 2024.
SGLT-2 inhibitors in type 2 diabetes. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305247/all/SGLT_2_inhibitors_in_type_2_diabetes
SGLT-2 Inhibitors in Type 2 Diabetes [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2024 October 11]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/1305247/all/SGLT_2_inhibitors_in_type_2_diabetes.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - SGLT-2 inhibitors in type 2 diabetes
ID - 1305247
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/1305247/all/SGLT_2_inhibitors_in_type_2_diabetes
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
